Please assess the completion status of the following clinical trial:

Trial Title: Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Proven disease,~* No betablocker at inclusion if previous CV event~Exclusion criteria:~Criteria of not inclusion for the RIGHTEOUS group:~* Patient having already presented an arterial break or a dissection and treated(handled) by bétâ-blocking(surrounding).~* Against indication in the use of CELIPROLOL:~* Unchecked cardiac insufficiency by the treatment~* cardiogenic shock~* BAV of 2nd and 3rd not sailed degrees~* angor of Prinzmetal~* disease of the sine~* bradycardia~* pheochromocytoma untreated~* low blood pressure~* sentimentality in the CELIPROLOL~* Antecedent of anaphylactic reaction~* myasthenia~* treatment by FLOCTAFENINE ( Idarac), Sultopride ( interactions ) In these two cases, the patient can be included in the group followed by troop.~Criteria of not inclusion for both groups:~* Refusal to participate in the study.~* Impossibility to move.~* Pregnancy~* Woman in age to procreate without means of effective contraception.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Celiprolol

Based on this trial design, predict the completion outcome and termination type (if applicable).